New Indication for Aldose Reductase Inhibitors?
Posted by WH in News, tags: diabetes, inflammation, respiratory disease, target identification
The physiological role of aldose reductase (AR) is still incompletely understood, although it has long been associated with the pathogenesis of diabetes-associated diseases such as cataract and neuropathy. In the last twenty years a number of AR inhibitors have entered clinical trials for the potential treatment of diabetic neuropathy. Whilst the compounds have generally been well tolerated, efficacy has not been clearly established (although one compound, Epalrestat, is approved in Japan for treatment of subjective neuropathy symptoms associated with diabetic peripheral neuropathy).
The rationale for use of AR inhibitors in diabetic complications is based on the ability of AR to reduce glucose to sorbitol, levels of which are elevated in tissues of diabetic patients. Although glucose does not have high affinity for AR, the pathway is believed to be relevant in hyperglycaemia.
AR is also known to reduce lipid aldehydes and their glutathione conjugates in response to reactive oxygen species (ROS). The products of the AR-catalysed reduction mediate activation of NFκB and the subsequent generation of inflammatory proteins. This observation led researchers at University of Texas Medical Branch and Louisiana State University Health Sciences Center to hypothesise that AR inhibitors may be useful in inflammatory diseases such as asthma. In a study published in PLoSone, the scientists stimulated primary human small airway epithelial cells (SAEC) with ragweed pollen extract (RWE). In this in vitro experiment, AR inhibition prevented RWE-induced apoptosis and expression of inflammatory mediators. Further, AR inhibition prevented allergic airway inflammation in mice sensitised with endotoxin-free RWE.
The results encourage exploration of AR inhibitors in inflammatory diseases such as asthma.
Related posts:
- TRPA1 Linked to Asthma Asthma involves an immune response to inhaled allergens and chemical irritants, but the limited efficacy of existing treatments aimed at...
- A-NO-ther Incarnation for COX Inhibitors? Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the risk of gastrointestinal side effects associated with the older non-steroidal anti-inflammatory...
- β2-Inverse Agonists for Asthma? β2-Adrenergic receptor agonists, which act directly on smooth muscle in the airways causing dilation and increased air flow, are standard...
- Topical Deferoxamine Could Help Diabetic Wound Healing In people with diabetes, damage to peripheral nerves and blood vessels means that wounds can initially go unnoticed, leading to...
- Childhood Asthma Linked to Common Cold The prevalence of asthma is increasing, with up to one in four urban children now affected. Episodes may be triggered...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Monday, August 10th, 2009 at 8:34 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Entries (RSS)